Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

Johnson & Johnson Stock Has Major Support on the Chart

Johnson & Johnson affirmed its full-year outlook and announced a new $5 billion buyback. Should you be a buyer right now?

The Street

Johnson & Johnson Stock Gains After Unveiling $5 Billion Buyback Program, Repeating Profit Targets

"We have the ability to invest in innovation, grow our dividend, execute strategic acquisitions, and take this action to deliver shareholder returns," said CEO Joaquin Duato.

The Street

Pelvic mesh class action $300m payout: but who will get the money?

Further details about the Johnson & Johnson class action are expected to emerge on Friday

Newcastle Herald

From analysis to the latest developments in health,
read the most diverse news in one place.

$300 million settlement for pelvic mesh class actions

In an announcement Monday, Shine Lawyers revealed the mammoth settlement which will go towards women injured by being implanted with Johnson & Johnson's pelvic mesh and vaginal tape devices.

Newcastle Herald

Check Out What Whales Are Doing With JNJ

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 12 strange trades.

Benzinga

Johnson Johnson Will Pay $300M To Women Who’ve Suffered From Pelvic Mesh Implant Complications

The settlement will help cover women's ongoing treatment for injuries caused by the mesh implants.

Pedestrian.tv

Pelvic mesh class actions settle for $300m

Two class actions against Johnson & Johnson over defective pelvic mesh products have settled for $300 million, finalising almost 10 years of legal fighting.

AAP

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson reaches $300m settlement over pelvic mesh implants

Settlement of two Australian class actions is largest in country’s history and subject to federal court approval

The Guardian - AU

Johnson & Johnson Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

This Is What Whales Are Betting On Johnson & Johnson

Someone with a lot of money to spend has taken a bullish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

The Covid Gambit: Pfizer, Moderna Struggle To Get The Jump On Covid

Companies are working to develop updated Covid boosters. Will they be too late to make a difference for the vaccine stocks — and society?

Investors Business Daily

Johnson & Johnson Whale Trades For August 23

Benzinga

Pharma funds Illinois pols, ‘Sister Jean’ turns 103, Honest Chicagoans talk Air and Water Show and more in your Chicago news roundup

Today’s update is a 5-minute read that will brief you on the day’s biggest stories.

Chicago Sun-Times

Illinois Senate President Don Harmon, other pols keep taking money from pharma companies implicated in opioid crisis

The Oak Park Democrat continues to accept campaign money from Johnson & Johnson, 1 of 4 companies paying $26 billion to settle suits accusing them of fueling the crisis. He’s not the only Illinois official doing so.

Chicago Sun-Times

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

If You Invested $1,000 In Johnson & Johnson Stock At Its COVID-19 Pandemic Low, Here's How Much You'd Have Now

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

Daily Record

Johnson & Johnson baby powder to be removed from all UK stores in 2023

The company cites commercial reasons and has blamed 'misinformation' over the safety of the product for its declining sales in the past.

The Street

Johnson & Johnson Stock: Here’s the Level to Buy, and It’s a Steal

Johnson & Johnson stock is hitting its lowest level since March. Here's where it's a steal of a deal.

Tribune News Service

More than a half billion doses of COVID vaccine made in Baltimore dumped, congressional panel finds

BALTIMORE — The tally of wasted COVID-19 vaccine continues to climb at the troubled Emergent BioSolutions plant in East Baltimore and now exceeds a half billion doses, according to findings a congressional panel released Thursday on the manufacturer once central to the U.S. coronavirus pandemic response.

Get all your
news in one place.

100’s of premium titles.
One news app.

Los Angeles Times

Walgreens fueled San Francisco's opioid crisis with thousands of 'suspicious orders,' judge rules

Walgreens helped fuel the opioid epidemic in San Francisco by shipping hundreds of thousands of "suspicious orders" of prescription drugs to its pharmacies, a federal judge ruled Wednesday.

The Street

Novavax Stock Plummets After Slashing 2022 Vaccine Sales Forecast

"I believe we were late to the market and US vaccination was driven by what was available and shown to work," said Novavax CEO Stanley Erck.

Benzinga

Johnson & Johnson Whale Trades Spotted

WEKU

New book chronicles how America's opioid industry operated like a drug cartel

Two Washington Post journalists say pharmaceutical companies collaborated with each other — and with lawyers and lobbyists — to create laws to protect the industry. Their new book is American Cartel.

Benzinga

Johnson & Johnson Whale Trades For July 25

Benzinga

Things Looking Up at Johnson & Johnson?

Johnson & Johnson (NYSE: JNJ) released their financial report for the second quarter of 2022, this week, demonstrating strong growth and promising guidance for the rest of the year. Analysts seem to agree, as the consensus rating for JNJ is MODERATE BUY.

Investors Business Daily

Stock Market Rallies On Earnings Lift; FAANG Stocks Lead The Way

The stock market closed higher on Tuesday on solid earnings reports and economic news, led by FAANG stocks.

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.